Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

December 7-10, 2019; Orlando, Florida
Venetoclax plus navitoclax (combined with chemotherapy) was well tolerated with promising efficacy in heavily pretreated patients with R/R ALL and LL.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: December 9, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: April 29, 2022

Download this online resource developed for healthcare professionals with a helpful guide for antibody-based therapies in B-cell lymphoma

Released: April 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings